Global CHC Market Movers, MAT Q1 2021

We have now published our latest Market Movers update on the CHC Dashboard website, highlighting 6 brands that have been driving growth in the global CHC market in the MAT Q1 2021 period, as well as 6 brands in fast decline, and below we look at the trends behind these exceptional brand performances.

Given that antiseptics & disinfectants were by far the biggest growth driver in the global CHC market in MAT Q1 2021, it’s no surprise that two of the six fastest-growing brands were hand sanitisers, Unilever’s Suave and ArtNaturals (ArtNaturals). Both were standout performers in the US market among a raft of new entries in the vibrant subcategory.

Rx-to-OTC switch has also been an important growth driver, with GSK’s May 2020 launch of topical analgesic Voltaren Arthritis Pain the notable development, generating sales in excess of US$100mn in under a year on the market. Former switch brand Plan B One-Step also performed exceptionally well in MAT Q1 2021, owing to limited access to prescribed contraception and family planning clinics during the pandemic. Foundation Consumer Healthcare also backed the brand with TV ads explaining it does not affect future fertility.

In China, the two fastest-growing CHC brands were Mayinglong Musk, a haemorrhoid preparation extended into new subcategories thanks to product innovation, and Fu Fang E Jiao Jiang, which marketer Dong-e E-jiao Group revived by returning to a policy of targeting general (not just high-end) consumers, helping ensure a return to growth overall for tonics & cure alls in China.

As for products that suffered falling sales in MAT Q1 2021, the clear majority (4 out of 6) were CCA brands, given the historically weak cough & cold season experienced by the industry in the first quarter of this year. Global No.1 brand Vicks posted further heavy decline in Q1, with MAT Q1 2021 sales falling by 24.5%; combo packs of Vicks NyQuil / DayQuil packs fell particularly hard (-54%).

Reckitt’s systemic cold & flu treatment Mucinex Fast-Max and cough remedy Delsym also suffered heavy decline in MAT Q1 2021, as did Taisho’s cold remedy Pabron in Japan, which was hit by the downturn for domestic and inbound channels attributable to Covid-related issues.

We are pleased to announce that Nicholas Hall’s North American e-Conference 2021 will take place on 21 September! Sponsored by Catalent, Nicholas will be joined by industry experts to explore Challenger Brands & Key Pillars to the New / Modern Marketing World. To register, or to find out more, please contact

Market Movers in MAT Q2 2020

To mark the publication of our latest Market Movers update, which picks out 6 brands driving growth in the global CHC market in the MAT Q2 2020 period, as well as 6 brands in fast decline, our blog this week examines the trends that are driving these exceptional changes.

Among the fastest-growing brands, one common thread is immunity positioning, with at least four of the six products highlighted below – Dabur Chyawanprash (India), Yiling Lianhua Qingwen (China), Airborne (USA) and Arbidol (Russia) – boosted by heightened demand for products that boost immunity during the pandemic.

TCM Yiling Lianhua Qingwen, available in China as capsules and granules, was listed in 2020 in the country’s Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme, while in April 2020, the National Medical Products Administration of China approved a new indication for “mild and common Covid-19” to be added on the basis of its originally approved indications. Sales for the brand in the MAT Q2 2020 period were up 68%.

Ayurvedic formulation Dabur Chyawanprash (Dabur) saw sales more than double (+169%) in MAT Q2 2020, driven by strong Covid-related demand and the launch of Dabur Immunity Kit in Q2 2020, to become India’s No.1 CHC brand. Likewise, umifenovir-based medicine Arbidol (OTCPharm), which is positioned for flu as well as acute respiratory and viral infections, also saw sales more than double (+103%) in the MAT Q2 2020 period and the brand now ranks in the Top 5 in Russia.

As for products that suffered falling sales in MAT Q2 2020, notable examples were tonics & cure alls in China – such as Dong-e E-Jiao – hit by rising raw material costs and falling demand, as well as ranitidine-based antacids – such as Sanofi’s Zantac 150 – owing to concerns around NDMA and Takeda’s Alinamin EX vitamin B supplement in Japan, affected by demographic changes and a fall in tourist spending.

If you would like to review the latest launches and NPD surrounding all the leading brands in the global CHC market, take a look at CHC New Products Trackerthe ultimate competitive intelligence tool! Featuring 26,000+ launches and innovations, products are graded with a star rating, and you can search according to your specific requirements. Please contact to set up your demo.

MAT Q1 2015 update: Three key Market Mover trends revealed

Our OTC DASHBOARD tutorial series continues, this time turning our attention towards the recently updated Market Movers section. I’ve outlined major MAT Q1 2015 growth drivers, such as US nasal steroids and Chinese health tonics, and included some tips and tricks to help you navigate the page. Meanwhile, Valeant has snapped up Sprout Pharmaceuticals and this week’s infographic looks back at its insatiable appetite for dealmaking – Regards, Owen Hartnett.

1. The Top 3 Market Movers were US OTC launches

The power of Switch was evident during MAT Q1 2015 with three product launches in the US recording the biggest change in total sales. Pfizer’s Nexium 24HR led the way generating US$201mn since its introduction in Q2 2014, following Rx-to-OTC switch approval, and continues to rapidly gain market share in the once ailing PPI antacids segment.

The emergence of a new OTC nasal steroids class is an important theme, with the next two biggest Market Movers being recently switched allergy remedies. Sanofi’s launch of Nasacort 24HR in early 2014 was the first 24-hour full prescription strength nasal allergy spray available in the US, and since then has garnered US$150mn in sales. More recently, in early 2015 Flonase (GSK) entered the fray, enjoying an impressive US$100mn in our reporting period, and is set to further expand this burgeoning category.

You can access these profiles at (requires login), where you will be presented with an overview of the Top 6 dynamic growth brands as well as those in decline. OTC DASHBOARD contains a handpicked selection to highlight major brands of interest, limited to no more than three from one country.

Screen Shot 2015-08-24 at 12.21.02

Quick tip: You can view each brand’s active ingredients, indication, tagline, nearest competitors and performance summary by clicking “More info”.

2. Chinese health tonics are on the rise

As you can see, Chinese tonics & cure alls are well represented in our Top 6, determined by the cost of raw materials and price rises. Dong-e E-jiao (Dong-e E-jiao Group) capitalised on strong growth of donkey hide e-jiao products, having had an 18% price increase in March 2014, and sales of “The nation’s tonic treasure” reached US$303mn in the 12 months to March 2015.

Qinghai Spring’s Very Grass grew by 22%; however, this represents a slowdown on its historical performance driven by reduced costs of caterpillar fungus following a nationwide crackdown on use of public funds to purchase premium gifts. Caterpillar fungus is one of the ingredients covered in China’s Development Plan for Raw TCM (2015-2020), which aims to strengthen quality and safety inspection of raw TCM and modernise its production and distribution.

3. Global supply issues hit smoking control category

Casting an eye over those Market Movers that posted a negative performance, we find that GSK’s smoking control business ran into several issues. Intense competition from e-cigarettes and the recall of Nicorette Mini lozenges caused many consumers to switch to private labels, damaging US sales of Nicorette, with growth down by -17% in our reporting period.

Screen Shot 2015-08-24 at 10.50.26

Quick tip: You can easily switch between growing and declining brands using the respective buttons on top.

Over in the UK, sales of NiQuitin CQ dipped by -49%, with the impact of the early 2014 recall of lozenge formats still being felt. GSK has struggled with supply issues globally, including NRT supply for Nicabate in Australia, and recalls of obesity treatment Alli in the US (this caused the OTC category to be wiped out almost entirely), although the marketer says it has now fixed such issues. In Q3 2015, GSK will divest key smoking control brands like NiQuitin to Perrigo, in connection with its consumer health j-v with Novartis.

Don’t forget, you can also view the Top 10 fastest-growing companies by Compound Annual Growth Rate (CAGR). Our CAGR table below takes the Top 100 OTC marketers globally, and then sorts this by their mean annual growth over the last five years (2014/2010, calculated in local currency). Please note, current figures refer to the full-year 2014 period.

Screen Shot 2015-08-24 at 11.42.22

Quick tip: Click the respective headings to sort the table by CAGR %, global rank or alphabetically.

Our Market Movers feature is powered by Nicholas Hall’s DB6 Global OTC Database. For the full list of brands, or if you have any questions regarding the wider database, please contact Kayleigh at:

For OTC DASHBOARD matters, get in touch at: